drugset / Trial / NCT01481545
Bevacizumab With Pelvic Radiotherapy And Primary Chemotherapy in Patients With Poor-Risk Rectal Cancer
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the use of chemotherapy, radiation therapy and bevacizumab before surgery in patients with locally advanced rectal cancer (LARC).
Timeline
- Start
- 2006-12
- Primary completion
- 2011-07
- Completion
- 2016-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 5 mg/kg | Intravenous |
| Background | Levoleucovorin | Unknown | 250 mg/m2 | — |
| Background | Oxaliplatin | Small molecule | 100 mg/m2 | — |
| Background | Raltitrexed | Small molecule | 2.5 mg/m2 | — |
| Background | fluorouracil | Small molecule | 800 mg/m2 | — |